Vertex Pharmaceuticals Incorporated (VRTX) Stock

Healthcare · Biotechnology · Member of S&P 500, NASDAQ 100

Vertex Pharmaceuticals Incorporated (VRTX) closed at USD 498.50 on 2026-10-14, a change of +18 % over the past year, with a market capitalization of USD 128.87B.

Vertex Pharmaceuticals Incorporated recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vertex Pharmaceuticals Incorporated key figures

Previous close

USD 498.50 (2026-10-14)

1-year change

+18 %

Market cap

USD 128.87B

Enterprise value

USD 123.07B

P/E ratio (trailing)

29.63

P/E ratio (forward)

25.30

EPS (trailing)

17.17

EPS (forward)

20.11

PEG ratio

1.95

Price to book

6.37

Revenue growth

12.5 %

Earnings growth

8 %

Dividend per share (trailing)

0.00

Short ratio

4.39

Employees

6,400

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vertex Pharmaceuticals Incorporated and compare it with other stocks.